Canada: Federal Court Applies Principle Of Claim Differentiation And Rejects Elevated "Promise" Of Utility For Compound Claims

Case: Novartis Pharmaceuticals Canada Inc. v Teva Canada Ltd. 2015 FC 770

Drug: EXJADE® (deferasirox)

Nature of case: Prohibition proceeding under Section 6 of the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations)

Successful party: Novartis Pharmaceuticals Canada Inc

Date of decision: June 19, 2015


O'Reilly J. granted a prohibition order sought by Novartis Pharmaceuticals Canada Inc. (Novartis) under section 6 of the PM(NOC) Regulations against Teva Canada Ltd. (Teva) in respect of its generic version of EXJADE® (deferasirox) and Canadian Patent No. 2,255,951 ('951 Patent). Teva alleged that the '951 Patent was invalid on various grounds, including inutility, obviousness and insufficiency of disclosure. In his assessment of utility, O'Reilly J. held that the use claims were subject to an explicit promise of use for treatment of excess iron in a human or animal body, and that this use was neither demonstrated nor soundly predicated as of the patent's filing date. The Court concluded, however, that this elevated promise did not extend to the compound claims of the patent. Teva's allegation that the '951 Patent as a whole was invalid for lack of utility was deemed unjustified.  

Claim differentiation in an allegation of inutility

Teva alleged that the explicit promise of the '951 Patent is that the claimed compounds had been shown to be valuable in the treatment of disorders involving excess iron in humans. Absent evidence of testing in humans as of the filing date, Teva contended that the stated utility of the patent had not been demonstrated; nor could any sound prediction be made that that utility could be achieved. Teva further alleged that this broad and overarching promise applies across all of the patent's claims, including the claims for novel compounds, whether or not the claims reference any particular utility.

O'Reilly J. emphasized that the utility requirement for patentability represents a fairly low threshold, unless the inventors explicitly promise a specific result, particularly if the stated utility is set out in the claims as opposed to the disclosure. However, as per the principles of claim differentiation set out by the Federal Court of Appeal in Apotex Inc v Pfizer Canada Inc, (2014 FCA 250 re: CELEBREX®), he reiterated that an explicit promise set out in the disclosure can apply to all claims but that it may be appropriate to distinguish between the promise of the compound claims, on the one hand, and the promise of the use claims, on the other, as in the present case.

In consideration of the above, O'Reilly J. rejected the part of Teva's allegation pertaining to the application of this promise to the patent's claims for novel compounds. In distinguishing these claims, he placed considerable emphasis on the '951 Patent's abstract, which makes clear that compounds claimed in the patent have "valuable pharmaceutical properties" which can be used for the treatment of iron overload conditions. It does not say that they have been used for that purpose, and it makes no reference to use in humans. He consequently held that all of the statements in the '951 Patent's disclosure cited by Teva merely provide support for the patent's use claims and not the compound claims.

The availability of prior art relied upon for an allegation of obviousness

In support of its allegation for obviousness, Teva argued that that the Patent Act (as per s 28.3) "no longer requires that the relevant prior art be discoverable on a reasonably diligent search" and that it merely has to be "publicly available" at the relevant date, citing the Federal Court of Appeal's discussion on anticipation in Wenzel Downhole Tools Ltd v National-Oilwell Canada Ltd, (2012 FCA 333) and claiming that it equally applies to the obviousness analysis. O'Reilly J. pointed out that there nevertheless exists a body of jurisprudence that applied the test of the "reasonably diligent search" even after the enactment of s. 28.3 and that there is no reason to take a different approach here.

In addition, O'Reilly J. expressed "considerable doubt" that some of the sources cited by Teva would have formed part of the relevant prior art, namely papers that were published in "obscure journals" that would likely not have been located by the skilled person looking for information on iron chelators.

Allegation of insufficient disclosure

Teva alleged that the disclosure of the '951 Patent does not allow a skilled person to work the invention claimed in the patent, that the skilled worker would not know which of the 30 novel compounds claimed would be effective in treating iron overload disorders and that the "real invention" of the patent was "buried" in claim 32. O'Reilly rejected this argument as being premised on a faulty construction of the '951 Patent by Teva. He held that the patent in suit relates to novel compounds that bind markedly to iron, are soluble in vivo, and induce excretion of the resulting iron complex. He emphasized that all 30 of the claimed novel compounds were demonstrated or soundly predicted to have those properties, and the patent describes how to synthesize all of them. The patent also provides the skilled person with information about the tests that were used to assess the activity of the compounds in vivo.

Link to decision:

The decision may be found here.

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Bereskin & Parr LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Bereskin & Parr LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions